dextroamphetamine extended release capsule / Generic mfg. - LARVOL DELTA

Co-occurring Anxiety in a Child With Autism and ADHD. (PubMed, J Dev Behav Pediatr) - "Based on his developmental history, physical examination, review of school-based testing, and parent- and school-completed standardized questionnaires, he met Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for autism spectrum disorder and ADHD with combined presentation.When KM was between the ages of 8 and 10 years, he trialed several medications, including methylphenidate (which led to emotional lability), dextroamphetamine sulfate oral solution (which caused irritability), and clonidine (which led to destructive behavior)...He eventually was stabilized on extended-release dextroamphetamine-amphetamine at the age of 9 years, which both parents agreed was helpful for improving attention, despite the medication triggering a new self-injurious behavior of punching himself.At the age of 10 years, after 1 year of stability on dextroamphetamine-amphetamine extended-release capsule 10 mg daily, his parents chose not to refill the..."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • CNS Disorders • Genetic Disorders • Mental Retardation • Mood Disorders • Pediatrics • Psychiatry

Targeting Anhedonia in Cocaine Use Disorder (clinicaltrials.gov) - P2 | N=57 | Completed | Sponsor: University of Illinois at Chicago | Recruiting ➔ Completed

Trial completion

Hypertensive Emergency Secondary to Combining Psilocybin Mushrooms, Extended Release Dextroamphetamine-Amphetamine, and Tranylcypromine. (PubMed, J Psychoactive Drugs) - "The patient was diagnosed with a myocardial infarction and treated with lorazepam, nitroglycerin, and aspirin. We suspect phenylethylamine, found in Psilocybe cubensis and other species of psilocybin mushrooms, interacted with tranylcypromine and dextroamphetamine-amphetamine to produce this hypertensive emergency. Patients prescribed MAOIs should be warned of the potential for hypertensive emergency when consuming psilocybin mushrooms, particularly when also prescribed norepinephrine releasers such as dextroamphetamine-amphetamine."

Journal • Cardiovascular • CNS Disorders • Depression • Hypertension • Major Depressive Disorder • Mood Disorders • Myocardial Infarction • Pain • Psychiatry

Neurobehavioral Mechanisms of Cocaine Choice (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Joshua A. Lile, Ph.D. | Trial completion date: Apr 2024 ➔ Feb 2025 | Trial primary completion date: Apr 2024 ➔ Feb 2025

Trial completion date • Trial primary completion date

A review of amphetamine extended release once-daily options for the management of attention-deficit hyperactivity disorder. (PubMed, Expert Rev Neurother) - "Rapid onset of action and a favorable side effect profile make these widely used. The availability of once-daily extended-release chewable tablets, capsules that can be opened and sprinkled, and liquid formulations provides clinicians with multiple options to meet the specific needs of patients with difficulty swallowing whole pills."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Pediatrics • Psychiatry

Therapeutic Interchange Cost-savings Initiative: Lisdexamfetamine to Amphetamine/dextroamphetamine ER (ASHP 2022) - No abstract available

HEOR

Neurobehavioral Mechanisms of Cocaine Choice (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Joshua A. Lile, Ph.D. | Trial completion date: Oct 2023 ➔ Apr 2024 | Trial primary completion date: Oct 2023 ➔ Apr 2024

Trial completion date • Trial primary completion date

Neurobehavioral Mechanisms of Cocaine Choice (clinicaltrials.gov) - P1; N=18; Recruiting; Sponsor: Joshua A. Lile, Ph.D.; Not yet recruiting ➔ Recruiting; Trial completion date: Apr 2023 ➔ Oct 2023; Trial primary completion date: Apr 2023 ➔ Oct 2023

Enrollment open • Trial completion date • Trial primary completion date

Targeting Anhedonia in Cocaine Use Disorder (clinicaltrials.gov) - P2; N=80; Recruiting; Sponsor: University of Illinois at Chicago; Trial completion date: Apr 2021 ➔ Apr 2022; Trial primary completion date: Apr 2021 ➔ Apr 2022

Trial completion date • Trial primary completion date

Neurobehavioral Mechanisms of Cocaine Choice (clinicaltrials.gov) - P1; N=18; Not yet recruiting; Sponsor: Joshua A. Lile, Ph.D.; Initiation date: Sep 2020 ➔ Jan 2021

Trial initiation date

Neurobehavioral Mechanisms of Cocaine Choice (clinicaltrials.gov) - P1; N=18; Not yet recruiting; Sponsor: Joshua A. Lile, Ph.D.; Initiation date: Jun 2020 ➔ Sep 2020

Trial initiation date

Neurobehavioral Mechanisms of Cocaine Choice (clinicaltrials.gov) - P1; N=18; Not yet recruiting; Sponsor: University of Kentucky; Trial completion date: Aug 2024 ➔ Apr 2023; Trial primary completion date: Aug 2023 ➔ Apr 2023

Trial completion date • Trial primary completion date

Neurobehavioral Mechanisms of Cocaine Choice (clinicaltrials.gov) - P1; N=18; Not yet recruiting; Sponsor: University of Kentucky

New P1 trial